SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (1773)7/20/2007 2:27:36 PM
From: dvdw©  Respond to of 7242
 
all good points, i'll be in touch.



To: richardred who wrote (1773)4/7/2008 7:12:03 AM
From: richardred  Read Replies (1) | Respond to of 7242
 
Novartis to buy Nestle's Alcon stakes for $39 billion
Monday April 7, 4:25 am ET
By Sam Cage

ZURICH (Reuters) - Novartis AG (VTX:NOVN.VX - News) has agreed to buy Nestle AG's (VTX:NESN.VX - News) 77 percent stake in U.S. company Alcon (NYSE:ACL - News) in a deal worth up to $39 billion to boost its eye care business, the Swiss drugmaker said on Monday.

Novartis will acquire a first, 25 percent stake in Alcon for $11 billion and is set to buy Nestle's remaining 52 percent for a fixed price of $28 billion between January 2010 and July 2011.

"The margins are higher than our pharma business and are obviously very attractive," Novartis Chief Executive Daniel Vasella told reporters.

Novartis is keen to broaden its business from prescription drugs, which face increasing competition from generic medicines and a tougher path to markets, to non-traditional areas like vaccines, eye care and generics.

The price of the first stake is at a 4 percent discount to Alcon's closing price on Friday.

Novartis, Europe's second-largest pharmaceuticals company by market capitalization, would pay a 22 percent premium to Alcon's closing price if it went ahead with the purchase of the second tranche.

Nestle can force through the purchase of the second tranche, but Novartis can opt out if there is a material change in the business, Novartis said.

The acquisition of the first stake values Alcon at 22.8 times expected 2008 earnings and the possible second step at a 2010 multiple of 22.5, according to Novartis.

The DJ Stoxx European pharmaceuticals sector is trading at an average 2008 multiple of 13.6 times.

The deal represents "a very rich price in our view despite the double-digit growth projected for the company (Alcon)," WestLB analyst Andreas Theisen said in a note.

Nestle, the world's largest food group, said the transaction would have a positive effect on its 2008 earnings per share. Shares in Nestle were 2.15 percent higher at 522.50 Swiss francs by 0739 GMT.

Novartis shares fell 0.6 percent to 52.10 francs.

"Alcon's sales and margins are clearly higher than Novartis's. However, the takeover structure may make cost savings difficult for several years," said Landsbanki Kepler analyst Denise Anderson.

"In addition, like all pharmaceutical companies, Alcon has some patent risks. We therefore see the deal as mostly neutral to Novartis," Anderson said.

COMPLEMENTARY

Alcon, which makes medical devices and medicines for eye care as well as contact lens care products, will complement Novartis's own contact lens unit Ciba Vision.

Alcon, the world's largest eye care company with sales of $5.6 billion, will add to Novartis's own contact lens and eye medicine business, which had 2007 revenues of about $2.5 billion.

Novartis said it would finance the purchase of the first stake in Alcon from its cash reserves and external short-term financing.

It would finance the possible purchase of the second stake from cash and further borrowing.

The deal will streamline Nestle, which has long described its stake in Alcon as financial. A Nestle spokesman said on Monday he did not foresee a decision on selling a stake in L'Oreal SA (Paris:OREP.PA - News) before 2009.

The sale of the Alcon stake, proceeds from which would be used to reduce debt, comes just before Nestle's annual shareholder meeting on Thursday.

Outgoing chief executive Peter Brabeck, who led a string of acquisitions to expand Nestle's health focus, is due to hand over the reins to new CEO Paul Bulcke.

(Editing by Erica Billingham, Paul Bolding)
biz.yahoo.com



To: richardred who wrote (1773)4/18/2008 3:18:24 AM
From: richardred  Respond to of 7242
 
Hershey + Cadbury = Chocolate Bliss?
By Colleen Paulson April 16, 2008

5 Recommendations

Talk of a Hershey (NYSE: HSY) and Cadbury Schweppes (NYSE: CSG) merger is nothing new. A year ago, merger speculation was sparked by Cadbury's plan to delink its beverage and candy business. Fast-forward, and Cadbury is still in the process of legally separating the two businesses, even though they operate separately internally. Hershey is trying to revitalize profits and sales after a recent management shakeup. Is the marriage of two leading candy makers too sweet, or is it destined for a bitter end?

Prelude to a merger?
Cadbury's strong European market presence would certainly compliment Hershey's North American strength. And the combined Hershey-Cadbury could use its joint strength to expand in emerging markets, including China and India. Cadbury's Trident, Dentyne, and chocolate products (not to mention those yummy Sour Patch Kids) line up well with Hershey's chocolate products, Jolly Ranchers, and Twizzlers Licorice.

But just because two companies have distribution networks and product mixes that could work together doesn't necessary mean that the new company will succeed (look at DaimlerChrysler). The big question is whether these cultures can join together to become a productive industry leader.

The initial signal is that the companies should fit together well since Hershey and Cadbury have existing, successful business partnerships in place. Hershey sells Cadbury and Caramello products in the U.S., and York, Almond Joy, and Mounds products worldwide. Actually, if you ask some retailers, these candy companies are working together too well.

Milking profits?
Pittsburgh-based grocer Giant Eagle recently filed suit against Hershey, Cadbury, and competitors Nestle and Mars, claiming a $200 million overcharge on chocolate from 2002 to 2007. This is the fourth such lawsuit this year where grocers asserted that the candy companies are fixing their sweets prices.

Price fixing is one thing, but we all know that food inflation is real, as prices of staples, including milk, continue to rise. Cadbury admitted that it has recently boosted prices again, contributing to its 7% first-quarter revenue growth for confections (although an early Easter certainly didn't hurt). Cadbury isn't the only foodie raising prices. ConAgra (NYSE: CAG) and General Mills (NYSE: GIS) are among companies that have recently raised prices to protect profit margins.

It's hard to compare chocolate and candy to peanut butter and cereal as far as having pricing power. Especially in today's weight-conscious world, people are looking for ConAgra's Healthy Choice and General Mills low-calorie cereals to round out their diets. It remains to be seen whether chocolate makers can continue to raise prices without real sales and volume ramifications.

One thing is certain -- Hershey and Cadbury need a spark to trigger stock price growth. Both stocks have taken a hit, with a 34% drop for Hershey, a 19% decline for Cadbury, and the stock prices lingering near 52- week lows.

This isn't the first time that Hershey has been the subject of acquisition talks. Wrigley (NYSE: WWY) proposed a $12 billion acquisition deal in 2002, which Hershey firmly rejected. With the recent management issues, Hershey may not be able to hold off a deal this time. And it may not make sense to.

Both Hershey and Cadbury are continuously looking for new products and partnerships to boost their market positions, expanding into sugarless candies and organic chocolate. Hershey has even set up a strategic partnership with Starbucks (Nasdaq: SBUX) to market Starbucks-branded candies. A combined Hershey-Cadbury would benefit from economies of scale, have the resources to grow internationally, and continue new product development efforts through internal work. Small acquisitions or business alliances would also likely be possible even in a challenging market.

And who wouldn't like the idea of Sour Patch Kids covered in Hershey's chocolate?

For related Foolishness:
fool.com



To: richardred who wrote (1773)4/22/2008 12:55:02 PM
From: richardred  Read Replies (2) | Respond to of 7242
 
New Buy today-HSY-to establish a position-35.38.



To: richardred who wrote (1773)9/14/2011 11:00:37 AM
From: richardred  Read Replies (2) | Respond to of 7242
 
Nestle Using Strong Franc in Takeovers Puts Mead Johnson in Play: Real M&A

Nestle Using Franc Makes Mead Johnson Takeover Target

Gianluca Colla/Bloomberg


An employee oversees a conveyor belt system which fills tins with baby food supplements manufactured at Nestle's new production unit for probiotic infant formulas in Konolfingen.




An employee oversees a conveyor belt system which fills tins with baby food supplements manufactured at Nestle's new production unit for probiotic infant formulas in Konolfingen. Photographer: Gianluca Colla/Bloomberg





Play Video
Q


Aug. 10 (Bloomberg) -- Jon Cox, analyst and head of Swiss research at Kepler Capital Markets, discusses Nestle SA's first-half results reported today and acquisition outlook. He speaks from Zurich with Owen Thomas on Bloomberg Television's "Countdown". (Source: Bloomberg)



Enlarge image
Nestle SA Chief Financial Officer James Singh

Craig Ruttle/Bloomberg


Nestle SA Chief Financial Officer James Singh.




Nestle SA Chief Financial Officer James Singh. Photographer: Craig Ruttle/Bloomberg




Nestle SA (NESN) is turning to takeovers after more than $10 billion in stock repurchases failed to stem a decline in shareholder value. That may put Mead Johnson Nutrition Co. (MJN) in its sights.

Nestle, which spent 10 billion Swiss francs ($11.4 billion) on buybacks in the past 14 months, will stop buying shares and may instead pursue acquisitions, Chief Financial Officer James Singh said last month after the currency reached a record. The world’s largest food company lost 5.4 percent during the buyback period as its rivals gained. While Nestle’s revenue is projected to drop this year, the franc’s appreciation -- the biggest of any major currency in the past year -- is now making takeovers cheaper than ever, James Investment Research Inc. said.

Buying Mead Johnson, the world’s largest standalone baby formula maker, would help Nestle revive growth and rebuild its business in China, the only major market where the company isn’t one of the biggest sellers of infant nutrition after authorities there found in 2005 that its products contained too much iodine. With Pfizer Inc. (PFE) delaying a sale of its own baby formula unit, according to people with direct knowledge of the plan, a deal for Mead Johnson instead would give Nestle more than half the U.S. baby food market, according to Euromonitor International.

“This is an asset that works best in Nestle, more than anywhere else,” Tom Pirko, president of Bevmark LLC, a Buellton, California-based consulting firm, said in a telephone interview. The firm counts Nestle as a client, according to its website. “Everything we’ve looked at so far says this is a very good fit, and it is a deal that should be put together.”

Shareholder Returns Nina Caren Backes, a spokeswoman at Vevey, Switzerland- based Nestle, declined to comment on whether it is considering a takeover of Mead Johnson. Chris Perille, a spokesman for Mead Johnson in Glenview, Illinois, declined to comment on whether it was approached by Nestle or would consider a sale.

“We never comment on marketplace speculation,” Perille said in a telephone interview.

Mead Johnson shares climbed as much as 3.1 percent and were up 2.1 percent to $74.04 at 10:20 a.m. in New York today. Nestle slipped 0.6 percent to $48.78 in Zurich.

Nestle, which purchased more than 188 million of its own shares in its latest plan, said Aug. 10 that it decided against buying more of its common equity. The program, completed last week, didn’t keep Nestle from declining over the 14-month span, according to data compiled by Bloomberg.

‘Create Value’ Companies that sell consumer staples in the MSCI World Index of developed markets advanced an average of 16 percent.

In the previous three years, Nestle had bought back 25 billion francs worth of stock, coinciding with a 6 percent gain.

“The share buyback hasn’t been as successful as they believed it would be,” said Joerg de Vries-Hippen, Frankfurt- based chief investment officer for European equities at Allianz Global Investors, which oversees more than $100 billion, including Nestle shares. “In the end, it didn’t create value.”

The announcement to end Nestle’s buyback program came one day after the franc climbed to an all-time high against the dollar on Aug 9. While the Swiss currency retreated after the nation’s central bank last week said it would cap the franc’s rate for the first time since 1978, it has still appreciated 14 percent in the past year, data compiled by Bloomberg show.

“Given the fact that there are potential alternative uses for our cash, such as investments in capabilities and bolt-ons, that provide greater long term strategic value for our shareholders, we believe that today is not the right time to be launching a new share buyback,” Nestle’s Singh said Aug. 10.

Shunning Buybacks Nestle is shunning buybacks to pursue acquisitions as it tries to bolster growth. After reporting 87.9 billion francs in revenue last year, analysts estimate that Nestle’s sales will fall more than 5 percent this year.

That makes a takeover offer for Mead Johnson, which is forecast to increase earnings twice as much as Nestle in 2012, a “high possibility” this year, according to David Hayes, a London-based analyst at Nomura Holdings Inc.

“They’ve got a strong currency to take advantage of,” Barry James, president of James Investment Research in Xenia, Ohio, said in a telephone interview. His firm oversees $2.5 billion. “It makes perfect sense that they would be seeking that diversification abroad.”

While Nestle is the biggest seller of infant nutrition in the world, it has lost market share in China after being forced to withdraw two varieties of its Neslac milk powder in 2005 because they had iodine levels that exceeded Chinese norms.

Fake Milk Powder A year earlier, 13 babies died of malnutrition after being fed fake milk powder sold with false labels and no nutritional value. Three years ago, melamine-tainted milk powder sickened thousands of children in China and killed at least six infants. The incidents didn’t involve Nestle products.

“Consumers want products that come from pharmaceutical companies as it gives them greater assurance,” said Ildiko Szalai, an analyst at Euromonitor in London. That’s why “Mead Johnson became number one in China last year” as consumers moved away from Chinese brands, he said.

Acquiring Mead Johnson, the $14.8 billion company split off from Bristol-Myers Squibb Co. in 2009, would help Nestle leapfrog Danone (BN) and become the biggest seller of infant- nutrition products in China, the largest market for baby food.

Mead Johnson had 11.7 percent of China’s infant formula market last year, while Paris-based Danone’s share equaled 9.8 percent, data compiled by Euromonitor showed.

‘Brand Matters’ Nestle didn’t rank in the top five in China, where sales of baby food through 2015 are forecast to increase almost three times as fast as the industry average, the data showed.

“The main piece would be to get access to the Chinese market,” Mark Demos, a manager at Fifth Third Asset Management in Minneapolis, which oversees about $18 billion and owns Mead Johnson shares, said in a telephone interview. “Infant formula is one of those things where the brand matters. They simply cannot replicate it by building a franchise like Mead Johnson in China. Mead Johnson is established.”

In the U.S., Mead Johnson would help Nestle more than double its share of baby food sales to about 58 percent. A deal would also enable Nestle to market its Gerber baby food to consumers already using Mead Johnson’s Enfamil formula as their babies switch from milk to eating purees and solid foods, according to Nomura’s Hayes.

“Nestle is very able to make the U.S. business at Mead work” because of the Gerber business, Hayes wrote in a report dated Sept. 12. “Nestle would be able to target more mothers in the U.S. with umbrella branded Gerber-Enfamil Formula.”

Nomura estimates that Nestle would have to pay at least a 25 percent premium to buy Mead Johnson, which would equal $18.5 billion. That would make the baby formula maker Nestle’s biggest acquisition on record, as well as one of the most expensive based on earnings before interest, taxes, depreciation and amortization, data compiled by Bloomberg show.

“Mead Johnson is not going to come cheaply,” Fifth Third’s Demos said. Still, “if you’re a consumer products food company worldwide and you want access to growth, Mead Johnson is a company that would achieve that for you.”

To contact the reporters on this story: Dermot Doherty in Geneva at ddoherty9@bloomberg.net; Tom Randall in New York at trandall6@bloomberg.net; Rita Nazareth in New York at rnazareth@bloomberg.net.

To contact the editors responsible for this story: Daniel Hauck at dhauck1@bloomberg.net; Katherine Snyder at ksnyder@bloomberg.net; Celeste Perri at +31-20-589-8505 or cperri@bloomberg.net.
bloomberg.com